Trial Profile
NEOADJUVANT EPIRUBICIN-OXALIPLATIN-XELODA AND OXALIPLATIN-XELODA-RADIOTHERAPY IN LOCALLY ADVANCED, RESECTABLE, GASTRIC CANCER. A PHASE II COLLABORATIVE STUDY.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2011
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Epirubicin (Primary) ; Oxaliplatin (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms NEOX-RT
- 30 Jul 2011 New trial record